Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will be interesting if we reach Float numbers.
Float is 53.89M
Traded so far today: 48M
Trading in a short price range today so will be interesting to see how it closes.
I can see some people doing day trading and taking lil profit by buying large shares and selling at short profits.
I could not imagine shorting on a day like today.
I would hate to think of shorting on a day like today, not knowing what could happen in this stock today or tomorrow in pricing. I could see them covering there shorts from before, but not doing any shorts now but who knows.
I noticed that 1,000,000 share traded logged as well. It was noted that the average cost of those million shares was .3051.
NVLT Thought.
With almost 14 million of the 17 million shares trading around .30ish, I would not be surprised if this drops more a lil later today. It may still rise up, but do not be surprised if it should fall into the twenties. Just my thought on how it is trading. I was hoping more of spreading the shares out in price ranges, but seems to be holding pretty steady in the .30xx's.
Kind of reminds me how ANX has been flattened out over time to trade in a small bandwidth. I hope that is not the case here, but will see over time.
APPA (2.00)
NVLT thought - close 1.65 open today .30
I do not wish this to happen to ANX, btu wanted to post this for others who may like to day trade or take risk on a shear drop and then possible rise - but could still fall more. I do not wish this or expect this on ANX.
Just wanted to pass on something that happened to NVLT this morning. The stock closed yesterday @ 1.65 after a nice rise in the day. This morning the news out was that NLVT Trial Does Not Meet Primary Survival Endpoint with FDA.
The stock opened on a huge loss this morning. I was able to buy in at .30, so I am hoping that this will be a nice bounce here. It could turn out to be a lose and fall into the teens.
Anytime a stock falls 75-80% in a day, I like to look at doing a daytrade with it, or buy possibly at end of day if it keeps falling and expect a pop in the next morning trade, possibly even in pre-hour trading.
NVLT in @ .30 in first minute of open.
I know this is a big risk, but worth seeing what happens today.
It may be that it goes down to the teens, or like another stock the other day that rose back 50% over the next couple of days from it sell off earlier.
NVLT (.36) I am not sure why I can not trade it on ARCA or NSDQ as I should be able to between 8 am and 8 pm.
I wonder if the exchanges are only buying up and not really selling? On E*Trade, I do not see any trade amount ticking since 8:34 am. On Fidelity I see the shares/bids ticking off, some from Nasdaq and some from OTC trades.
I am guessing if it was fully open though that we would see a much higher volume being traded.
I have seen this happen before... a stock is halted, and some of the exchanges test their system to be sure it works ok with such a price drop. I don't understand it but have seen it before and felt that is what they were doing.
We will just have to wait and see.
Yes. All being rejected. I am guessing they are tesing the systems for NVLT expecting a large price drop. I am just surprised there are no notices of it being halted if it is.
Yes he did. I sold and took profit yesterday, but looking at this as a possible day trade if we are dropping this much this early.
NVLT: My two brokerage agencies will not let me do any trading on this stock. They are rejecting either the symbol as being valid or rejecting the offer I am placing on it from my other agency. I do see trades taking place at least on OTCBB.
I do not see any messages saying trading has been halted for this stock, and I am seeing trades shown up now throught Nasdaq. I will have to try again. Bids, if valid and not testing, have been in the .65 range lately.
NVLT (1.20) Trial Does Not Meet Primary Survival Endpoint
Novelos Therapeutics Pivotal Phase 3 Lung Cancer Trial Does Not Meet the Primary Survival Endpoint
Detailed Trial Results Expected in 2010 02/24 08:30 AM
(More and more news coming out as I post this, can not keep up with all news reports here.)
NEWTON, Mass.--(BUSINESS WIRE)-- Novelos Therapeutics, Inc. (NVLT:$1.65,00$0.26,0018.71%) , a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.
This randomized, controlled, open-label Phase 3 trial, conducted under a Special Protocol Assessment (SPA) and Fast Track designation, had enrolled 903 patients with Stage IIIb/IV NSCLC, which includes all histological subtypes. The trial, conducted across approximately 100 clinical sites in 12 countries, evaluated NOV-002 in combination with first-line paclitaxel and carboplatin chemotherapy versus paclitaxel and carboplatin alone. The primary efficacy endpoint of the trial was improvement in overall survival. Enrollment commenced in November 2006, target enrollment was achieved in March 2008, and the 725 event (patient death) was announced in early January 2010. According to the trial’s Statistical Analysis Plan (SAP), a total of 725 events were required to detect a 25% improvement (12.5 months versus 10 months) in overall median survival (hazard ratio of 0.8) with 85% power and a two-sided significance level of 0.05. No interim analysis was performed.
“We are very disappointed that our pivotal Phase 3 lung cancer trial did not meet the primary survival endpoint,†said Harry Palmin, President and CEO of Novelos. “We were hopeful of a positive outcome based on our statistical model simulations and stated assumptions. In retrospect, it appears our simulations were inaccurate due to trial data deviating from our statistical model, the impact of censoring patterns, and control arm survival exceeding our expectations based on historical precedents. We will conduct a thorough analysis of all the data, and expect to present detailed Phase 3 lung cancer trial results later this year. Meanwhile, we are scheduled to present new NOV-002 preclinical data at the AACR Annual Meeting in April 2010, and we are on track for results from a NOV-002 Phase 2 breast cancer trial in 3Q 2010. We are also on track to initiate a Phase 2 hepatitis C trial shortly, with our second compound NOV-205.â€
About NSCLC
NSCLC accounts for about 87% of lung cancer, which is the leading cause of cancer death in the U.S. According to the American Cancer Society, approximately 215,000 people were expected to be diagnosed with lung cancer in 2008 in the U.S., with approximately 162,000 deaths. Approximately 1,500,000 new cases of lung cancer were expected worldwide in 2007 and approximately 1,350,000 deaths were projected from lung cancer in 2007. Only about 16% of NSCLC patients are diagnosed early enough to be eligible for surgery. Platinum-based chemotherapy regimens are standard first-line treatment for advanced NSCLC patients. During treatment, patients are subject to serious chemotherapy-induced adverse effects. According to results of 12 Phase 3 clinical trials published from 2001-2008, the one-year survival rate for patients receiving paclitaxel and carboplatin first-line therapy was on average only about 40%, the weighted average for median survival was 9.7 months and the objective tumor response (defined as greater than 30% tumor shrinkage) rate was about 27%. Overall, fewer than 5% of advanced non-small cell lung cancer patients survive five years. Improving on the standard of care in unselected advanced NSCLC remains challenging and elusive.
About NOV-002 for NSCLC
NOV-002 is a small molecule compound based on a proprietary formulation of oxidized glutathione that acts together with chemotherapy as a chemopotentiator and a chemoprotectant by regulating redox-sensitive cell signaling pathways. The pivotal Phase 3 trial of NOV-002 in 903 advanced NSCLC patients in combination with first-line chemotherapy did not meet the primary endpoint of improvement in overall survival. Previously, three separate Phase 2 trials demonstrated clinical activity and safety of NOV-002 in combination with first-line chemotherapy in NSCLC. NOV-002 has an extensive safety database, and has also demonstrated improved recovery from chemotherapy toxicity in cancer patients. NOV-002 does not appear to be chemotherapy specific or tumor specific.
About Novelos Therapeutics, Inc. (NVLT:$1.65,00$0.26,0018.71%)
Novelos Therapeutics, Inc. (NVLT:$1.65,00$0.26,0018.71%) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound that completed a Phase 3 trial for lung cancer, acts together with chemotherapy as a chemopotentiator and a chemoprotectant. NOV-002 is also in Phase 2 development for early-stage breast cancer and chemotherapy-resistant ovarian cancer. Novelos has a partnership with Mundipharma, an independent associated company of Purdue Pharma, to develop and commercialize NOV-002 in Europe and Asia (excluding China). Novelos’ second compound, NOV-205, acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have been partnered with Lee’s Pharm in China. For additional information about Novelos please visit www.novelos.com.
Novelos Therapeutics, Inc. (NVLT:$1.65,00$0.26,0018.71%)
One Gateway Center, Suite 504
Newton, MA 02458
This news release contains forward-looking statements.Such statements are valid only as of today, and we disclaim any obligation to update this information.These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.These statements are based on our current beliefs and expectations as to such future outcomes.Drug discovery and development involve a high degree of risk.Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, ourpharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
Source: Novelos Therapeutics, Inc. (NVLT:$1.65,00$0.26,0018.71%)
I have my 27 day moving average @.306, and my 52 day moving average at .2898. They are getting closer so hopefully something will happen today or tomorrow.
6300 @ 0.30 in afterhours.
I was lucky enough to get an extra 6300 shares @ $0.30 through the Pacific Exchange. I put in an order for 10K @ .30 but did not expect any to fill. I usually try to do something just in case the MMs have to unload some for a reason, or trader wants to sell in extended hour trading.
I almost feel like I am waiting for my birthday to come around so I can open some presents.
Lots of 20K blocks being traded.
I am not sure how to take that, but in these last several minutes I am seeing a lot of 20,000 share blocks (.3083-.3089) being traded, or maybe exchanged across MMs. You can see this by the volume by minute across the day it spike up recently.
I just wish I knew, if anything, what this may mean.
BRCD (5.67) - been watching it all morning along with the other top nine most actively traded stocks on Nasdaq.
Waiting to see if it reaches a 20-25% drop before maybe buying in. Hard to tell right off what will happen on regular market open. Guessing it may rise a lil in pre-open house to help sell more shares at a higher price and than expecting another drop from a lot of sell orders being triggered and submitted.
But it is so hard to tell what could happen here as it could have hit bottom already and rise back up.
Just saw 5 million shares go across at 5.70 about 2 minutes ago. (9:28)
Yes it does work for me. Thank you.
The link does not work for me.
XNPT Sad Thing...
It is a sad thing if the phone call this morning was calling the FDA Response Letter a "non-issue", then it would have been nice for the company to hear that in given the notice two days ago, before the stock dropped from 19.60 to 6.67 in yesterday's trading. Luckily I was able to do some day trading with it nicely, but sad to see that the lose was a major one. It will be interesting to see what happens in the coming days to see if the stock can get about a 200% gain to get back to where it was at 19.60. I really doubt it, but will be interesting to follow.
I am and thank you for the suggestion. He is still very strong on it.
I just wished I held on for another 3 or so minutes before buying in at 1.90.... could have saved about 1K if I did. Made me think something was up when they filled my large order right away and nothing (shares available or bid price) changed on LEVEL II to reflect my purchase. Those things happen. Thanks again.
Thanks for the information.
I guess I was hoping that it was going to form a new baseline around $2 since we stayed there for about 3 days in closing I think, and about 4 days in that range of trading. Hopefully I will be able to get some additional funds cleared up and get some more to help level me out to a lower level.
Hopefully the next month comes with good news for me. Either a new job or a good run here before I have to withdrawl my IRA funds to keep paying the bills with this year.
A nice run today, it was long due for this. Let's hope for another solid day of climb.
Did not expect a large drop like that today. A 3rd straight drop. Did anyone see new news on this company today?
I remember watching this and seeing the stock doing good on days that the market was diving each day, so this really surprises me on the last 3 days.
APPA (1.73) Down over 10%, but I see no news. Anyone heard anything?
Any way to tell if a shorting was occuring?
Nothing worries me more...
Nothing worried me more than when I place a BUY order for XX,XXX shares, and they get filled right away and the numbers on LEVEL II do not change on the different exchange listings for shares and price.
Argh... as I thought.. the price just drop .03 per share 10 minutes after purchasing... hence why I worry when I buy and the numbers do not change on the exchanges. LOL... oh well... still will hold them.
Just thought I would share as I am sure others have seen this happen to them as well.
XNPT Stories on FDA CRL from 2/17
Interesting article from this morning, but I think they are a little off on where they thought it would be trading. This one you should be able to click on.
http://notablecalls.blogspot.com/2010/02/xenoport-nasdaqxnpt-ouch-now-this-is.html
=======================================
I am not sure if you will be able to click on this link as you may have to be a member, so I posted the whole article below: http://www.gsk.com/media/pressreleases/2010/2010_us_pressrelease_10013.htm
This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS
Issued: Wednesday, 17 February 2010, London, UK, Research Triangle Park, NC & Santa Clara, CA —GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
A Complete Response letter is issued by the FDA’s Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form. GSK and XenoPort are currently evaluating the Complete Response letter, in which the FDA indicated that a preclinical finding of pancreatic acinar cell tumors in rats was of sufficient concern to preclude approval of Horizant for RLS at this time. FDA acknowledged that similar findings were known for gabapentin at the time of its approval for refractory epilepsy, but concluded that the seriousness and severity of refractory epilepsy justified the potential risks. The companies are assessing the appropriate next steps and will be communicating with FDA.
The NDA was submitted to the FDA on January 9, 2009.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Gabapentin enacarbil is also being developed in partnership with Astellas Pharma Inc. for the potential treatment of Restless Legs Syndrome in Japan. XenoPort’s product candidates are being evaluated as potential treatments for patients with neuropathic pain, migraine (as prophylactic treatment), gastroesophageal reflux disease, spasticity and Parkinson’s disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
Conference Call and Webcast Information
XenoPort will host a conference call at 8:30 a.m. Eastern Time tomorrow. To access the conference call via the Internet, go to www.XenoPort.com. To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 1-706-679-1417.
The replay of the conference call may be accessed after 12:30 p.m. Eastern Time Thursday, February 18, via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers or 1-706-645-9291 for international callers. The reference number to enter both the call and the replay of the call is 58168197.
Editor’s Note: Horizant was formerly referred to by the proposed trade name Solzira™.
GlaxoSmithKline Enquiries:
UK Media enquiries:
Philip Thomson
(020) 8047 5502
Claire Brough
(020) 8047 5502
Stephen Rea
(020) 8047 5502
Alexandra Harrison
(020) 8047 5502
Jo Revill
(020) 8047 5502
US Media enquiries:
Nancy Pekarek
(919) 483 2839
Mary Anne Rhyne
(919) 483 2839
Kevin Colgan
(919) 483 2839
Sarah Alspach
(919) 483 2839
European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
Sally Ferguson
(020) 8047 5543
Gary Davies
(020) 8047 5503
US Analyst/ Investor enquiries:
Tom Curry
(215) 751 5419
Jen Hill Baxter
(215) 751 7002
XenoPort Enquiries:
Analyst/Investor enquiries:
Jackie Cossmon
(408) 616 7220
GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.
XenoPort Forward-Looking Statement
This press release contains "forward-looking" statements, including, without limitation, all statements related to the therapeutic and commercial potential of XenoPort’s product candidates and potential future interactions with the FDA related to the NDA for Horizant for the treatment of RLS. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "potential," “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to successfully conduct clinical trials of its product candidates, and the results thereof; the uncertainty of the FDA approval process and other regulatory requirements; XenoPort's dependence on its current and additional collaborative partners; and the therapeutic and commercial value of the company's compounds. These and other risk factors are discussed under the heading "Risk Factors" in XenoPort's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, filed with the Securities and Exchange Commission on November 4, 2009. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Horizant™ is a trademark of GSK. XenoPort is a trademark of XenoPort, Inc.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
(19.60) XNPT (7.00) Thought this was interesting.
Close yesterday for XNPT was 19.60, this morning it is trading around 7.00 at this moment. I did snatch up about 500 at 6.90 and waiting to see what actually happens, may be able to do a lil fast trade on it.
(at this time)
High this morning 10.00
Low this morning 6.85
volume 227,662
===================================================
XenoPort Swooning More than 60% on Increasing Pre-Market Volume - Gets FDA Complete Response Letter for Horizant 02/18 07:15 AM
07:15 AM Eastern Standard Time, 02/18/2010 (MidnightTrader) -- GlaxoSmithKline (GSK:$39.36,00$0.11,000.28%) and XenoPort (XNPT:$19.60,00$0.71,003.76%) received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
GSK and XenoPort (XNPT:$19.60,00$0.71,003.76%) are currently evaluating the Complete Response letter, in which the FDA indicated that a preclinical finding of pancreatic acinar cell tumors in rats was of sufficient concern to preclude approval of Horizant for RLS at this time. FDA acknowledged that similar findings were known for gabapentin at the time of its approval for refractory epilepsy, but concluded that the seriousness and severity of refractory epilepsy justified the potential risks. The companies are assessing the appropriate next steps and will be communicating with FDA.
Price: 7.44, Change: -12.1, Percent Change: -62
http://www.midnighttrader.com
Get more news on:SYMBOLS: XNPT, GSKNEWS TYPE: Pre-Market Movers, Extended TradingSECTORS: Pharmaceuticals, Health Care
2/17 Market on Close Sell Imbalance.
I noticed there was a Market on Close Sell Imbalance yesterday, which probably caused the one low trade price at the end of trading day to clear this out.
Thank you for the information. Some of it I knew but not the full story. And it was easy to follow along in what you said. Thanks again!
Question on Shorting....
I have never shorted before, or actually looked into it yet but maybe some day may do it. I am curious to know when someone shorts a stock, do they have a certain time to have it resolved in, that is to cover the short cell?
I may be thinking of Margins, but not sure. I seem to remember that some type of trading has a set limit and that as that time nears, it could make a stock react in an up or down price quite rapidly I believe.
I believe you.... lol... then stop looking at it in AH... just kidding. So hard to tell how things will go outside of normal trading hours as I have seen it follow through on the opening, or even do a complete reverse and nothing like the extended hours.
I am seeing the price up in Afterhours, not down... or am I missing something. Looks like most trades are at the .30 level.
Thanks... I like it also...
I picked up some more in the low $1.90s today.
I do hope we can close at $2 or more today, as I would like to see it stay above $2 from now through first part of March.
In NVLT @ 1.51.
(APPA) Form SC 13G/A AP PHARMA INC Filings
I can not remember if the last two reports were shown here or not, so I thought I would post all 3 of them.
Filed on: February 16, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: Boxer Capital, LLC 02/16 04:42 PM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6767261
Filed on: February 12, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: Flynn James E 02/12 02:50 PM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6757478
Filed on: February 12, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: ORBIMED ADVISORS LLC 02/12 09:33 AM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6754405
Form SC 13G/A AP PHARMA INC Filings
I can not remember if the last two reports were shown here or not, so I thought I would post all 3 of them.
Filed on: February 16, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: Boxer Capital, LLC 02/16 04:42 PM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6767261
Filed on: February 12, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: Flynn James E 02/12 02:50 PM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6757478
Filed on: February 12, 2010
Form SC 13G/A AP PHARMA INC /DE/ Filed by: ORBIMED ADVISORS LLC 02/12 09:33 AM
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6754405
Hello Everyone.
I wanted to say hello to everyone and let you know I would love to share in the board as I can.
I got into APPA earlier this last week, I think my 4rd trade to date (3 buys/1 sell orders) before I happen upon this board in seeing some comments about APPA.
I hope everyone has a wonderful holiday weekend and a great week next week.
Crammerfool (aka Larry)
I was one of those that bought APPA into the afterhours trading, right after the close. I did not feel the offer would be filled right away for me @ 1.94 for 9,000 shares, but it did, which then had me a little worried I was surprised to see it fill in whole so quickly. Then to see it rise up even higher from the close as the extended hours went on was also nice to see.
I will add that I was hoping to see it close above 2.00 versus just run up and then back down again. I feel it could help for some footing later on in a support level - at least I am hoping it will help.
Now that is very good information to know. Thank you.
It may have... I noticed alot of my stocks ran in the last 5 to 10 minutes.